Association between pCR, TILs, and Ki-67 at baseline and after 2 weeks in patients with triple-negative breast cancer (TNBC) treated with atezolizumab and chemotherapy plus /- a preceding atezolizumab monotherapy window: A translational analysis of the neoMono trial